HDAC inhibitors block innate immunity

Blood

Volumn 117, Issue 4, 2011, Pages 1102-1103

  Bode, Konrad A ^a   Dalpke, Alexander H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 12P40; INTERLEUKIN 6; STAT1 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRICHOSTATIN A; TUMOR NECROSIS FACTOR INHIBITOR; VALPROIC ACID;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE INDUCTION; GENETIC ASSOCIATION; HUMAN; INFECTION SENSITIVITY; INNATE IMMUNITY; INVASIVE CANDIDIASIS; KLEBSIELLA PNEUMONIAE INFECTION; MACROPHAGE; MACROPHAGE ACTIVATION; NEUTROPENIA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SEPSIS; SEPTIC SHOCK; SIDE EFFECT;

EID: 79251588726     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-315820     Document Type: Note

References (11)

1. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.
2. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007;16(7):1111-1120. (Pubitemid 47074165)
3. Bode KA, Schroder K, Hume DA, et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology. 2007;122(4):596-606. (Pubitemid 350075958)
4. Brogdon JL, Xu Y, Szabo SJ, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2007;109(3):1123-1130. (Pubitemid 46220659)
5. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines 1. Proc Natl Acad Sci U S A. 2002;99(5):2995-3000.
6. Roger T, Lugriu J, Le Roy D, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood. 2011;117(4):1205-1217.
7. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923-3931.
8. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759.
9. Ramirez-Carrozzi VR, Nazarian AA, Li CC, et al. Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 2006;20(3):282-296.
10. Krämer OH, Knauer SK, Greiner G, et al. A phosphorylation- acetylation switch regulates STAT1 signaling. Genes Dev. 2009;23(2):223-235.
11. Halili MA, Andrews MR, Labzin LI, et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol. 2010;87(6):1103-1114.